Yi Di Zhang

US Patent:

7619056, Nov 17, 2009

Filed:

May 31, 2007

Appl. No.:

11/809034

Inventors:

Anthony East - Madison NJ, US
Michael Jaffe - Maplewood NJ, US
Yi Zhang - Harrison NJ, US
Luiz H Catalani - Carapicuiba, BR

Assignee:

New Jersey Institute of Technology - Newark NJ

International Classification:

C08G 59/50
C07D 493/02

US Classification:

528421, 549464

Abstract:

Novel thermoset epoxy polymers using the bisglycidyl ethers of anhydrosugars, such as isosorbide, isomannide, and isoidide, are disclosed. The bisglycidyl ethers are useful as substitutes for bisphenol A in the manufacture of thermoset epoxy ethers. The anhydrosugars are derived from renewable sources and the bisglycidyl ethers are not xenoestrogenic and the thermoset curing agents are likewise derived form renewable resources.

US Patent:

7711420, May 4, 2010

Filed:

Mar 19, 2007

Appl. No.:

11/687957

Inventors:

Tamara Colette Baynham - Piscataway NJ, US
Quan Ni - Shoreview MN, US
Shelley M. Cazares - Washington DC, US
Kevin J. Stalsberg - White Bear Lake MN, US
Yi Zhang - Blaine MN, US

Assignee:

Cardiac Pacemakers, Inc. - St. Paul MN

International Classification:

A61N 1/00

US Classification:

607 9

Abstract:

Cardioprotective pre-excitation pacing may be applied to stress or de-stress a particular myocardial region delivering of pacing pulses in a manner that causes a dyssynchronous contraction. Such dyssynchronous contractions are responsible for the desired cardioprotective effects of pre-excitation pacing but may also be hazardous. Described herein is a method and system that uses measures of ventricular dyssynchrony or a patient's physiological response to ventricular dyssynchrony to control the delivery of cardioprotective pre-excitation pacing in closed-loop fashion.

US Patent:

7977050, Jul 12, 2011

Filed:

Sep 2, 2005

Appl. No.:

11/218838

Inventors:

Michael Seul - Fanwood NJ, US
Nataliya Korzheva - Somerville NJ, US
Jiacheng Yang - Hillsborough NJ, US
Yi Zhang - Hillsborough NJ, US

Assignee:

Bioarray Solutions, Ltd. - Warren NJ

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

A method mediated with in-vitro transcription (“IVT”) which permits miniaturization of multiplexed DNA and RNA analysis, and in which elongation-mediated multiplexed analysis of polymorphisms (eMAP) is used as the analysis step, is described. Also described is a method mediated with IVT is for selecting a designated strand from T7-tagged double stranded DNA: wherein, the selected strand forms the template for RNA synthesis. In one embodiment, double stranded DNA incorporating the T7 (or other) promoter sequence at the 3′ end or the 5′ end is produced, for example, by amplification of genomic DNA using the Polymerase Chain Reaction (PCR). Also disclosed are nested PCR designs permitting allele analysis in combination with strand selection by IVT. Further, in one embodiment of a homogeneous format for transcription-mediated amplification and multiplexed detection (which may be particularly suited for viral or pathogen detection), encoded microparticles display “looped” capture probe configurations permitting the generation of a signal upon capture of RNA product and real-time assay monitoring.

US Patent:

8340764, Dec 25, 2012

Filed:

Feb 17, 2011

Appl. No.:

13/029631

Inventors:

Tamara Colette Baynham - Piscataway NJ, US
Yi Zhang - Plymouth MN, US
Joseph M. Pastore - Concord OH, US

Assignee:

Cardiac Pacemakers, Inc. - St. Paul MN

International Classification:

A61B 8/14

US Classification:

607 9, 600508, 600439

Abstract:

A pacing system delivers cardiac protection pacing to protect the heart from injuries associated with ischemic events. The pacing system detects an ischemic event and, in response, initiates one or more cardiac protection pacing sequences each including alternative pacing and non-pacing periods. In one embodiment, the pacing system initiates cardiac protection pacing sequences including at least one postconditioning sequence to protect the heart from a detected ischemic event and a plurality prophylactic preconditioning sequences to protect the heart from probable future ischemic events.

US Patent:

20070093968, Apr 26, 2007

Filed:

Oct 23, 2006

Appl. No.:

11/585068

Inventors:

Yi Zhang - Hillsborough NJ, US
Michael Seul - Fanwood NJ, US

International Classification:

G01N 33/567
G06F 19/00

US Classification:

702019000, 435007210

Abstract:

Disclosed are methods for establishing the compatibility between two blood types on the basis of cross-matching (under a designated rule of stringency) the minor blood group genotypes of recipient and prospective donors. To determine compatibility, the blood group genotypes are mapped to corresponding phenotypes according to the expression states associated with a set of underlying haplotypes, and compatibility is established by establishing the compatibility of blood types constructed as a combination of constituent phenotypes. The bit strings are matched, preferably using an algorithm expression. Where ambiguity in mapping genotypes to haplotypes exists, it can be reduced based on frequency of occurrence of the haplotypes in the sample population, or resolved by gametic phasing. Such reduction or resolution of ambiguity is particularly desirable where mismatches in the antigens expressed by the constituent haplotypes have greater clinical significance.

US Patent:

20070100557, May 3, 2007

Filed:

Dec 9, 2005

Appl. No.:

11/298763

Inventors:

Yi Zhang - Hillsborough NJ, US
Michael Seul - Fanwood NJ, US

International Classification:

G06F 19/00

US Classification:

702019000

Abstract:

Disclosed are methods for establishing the compatibility between two bloodtypes on the basis of cross-matching (under a designated rule of stringency) the minor blood group genotypes of recipient and prospective donors. To determine compatibility, the blood group genotypes are mapped to corresponding phenotypes according to the expression states associated with a set of underlying haplotypes, and compatibility is established by establishing the compatibility of bloodtypes constructed as a combination of constituent phenotypes. The bit strings are matched, preferably using an algorithm expression. Where ambiguity in mapping genotypes to haplotypes exists, it can be reduced based on frequency of occurrence of the haplotypes in the sample population, or resolved by gametic phasing. Such reduction or resolution of ambiguity is particularly desirable where mismatches in the antigens expressed by the constituent haplotypes have greater clinical significance.

US Patent:

20070189990, Aug 16, 2007

Filed:

Feb 16, 2006

Appl. No.:

11/355936

Inventors:

Anthony East - Madison NJ, US
Yi Zhang - Harrison NJ, US
Michael Jaffe - Maplewood NJ, US

International Classification:

A61K 8/49
C07D 307/02

US Classification:

424059000, 549478000

Abstract:

Esters of cinnamic acids with sugar alcohols and anhydro-sugar alcohols are described. The esters have ultraviolet light absorbing properties. In particular, the diester of ferulic acid with isosorbide is a UV-absorber derived from natural materials and has use as a UV-absorber for polymeric materials and as a UV-absorber for cosmetics.

US Patent:

20070243534, Oct 18, 2007

Filed:

Apr 12, 2006

Appl. No.:

11/403100

Inventors:

Michael Seul - Fanwood NJ, US
Yi Zhang - Hillsborough NJ, US
Sukanta Banerjee - Pennington NJ, US
Jiacheng Yang - Hillsborough NJ, US
Chiu Chau - Edison NJ, US

International Classification:

C12Q 1/68
C12M 3/00

US Classification:

435006000, 435287200, 977924000

Abstract:

In a multiplexed assay method carried out in solution, wherein the solution contains nucleic acid targets and, wherein several different types of oligonucleotide probes, each type having a different sequence in a region designated as a target binding domain, are used to detect the nucleic acid targets, said assay method including a method for increasing the effective concentration of the nucleic acid targets at the surface of a bead to which the oligonucleotide probes are bound, by one or more of the following steps: adjusting assay conditions so as to increase the effective concentration of the targets available for binding to the probes, by one or more of the following: (i) selecting a particular probe density on the surface of the bead; (ii) selecting a solution having an ionic strength greater than a threshold; (ii) selecting a target domain of a size less than a threshold; or (iii) selecting target domains within a specified proximity to a terminal end of the targets.